Intra-articular use of radium dichloride ([223Ra] RaCl2) showed relevant anti-inflammatory response on experimental arthritis model.
Luana Barbosa CorrêaMaria das Graças Muller de Oliveira HenriquesElaine Cruz RosasRalph Santos-OliveiraPublished in: European journal of nuclear medicine and molecular imaging (2021)
Rheumatoid arthritis (RA) is an inflammatory chronic autoimmune disease. The treatment of RA is difficult and, in many cases, ineffective, and the arsenal of drugs is limited. Due the longevity of the disease, RA may cause extreme musculoskeletal disorders with a high impact on quality of life. Also, RA is related with severe comorbidities decreasing the life expectancy. Finally, RA has been reported to impact in economy and healthy public. In this direction, the necessity to discover new strategies to efficiently treat RA is immediate. In this direction, we have reported the use of low doses of [223Ra] RaCl2 (radium dichloride) as intra-articular injection to treat RA. Mice were post-treated with [223Ra] RaCl2 (1.48 µCi; i.a.) 24 h after zymosan stimulus. Zymosan-induced arthrithis is responsible for leucocyte recruitment (total leukocytes, neutrophils, and mononuclear cells), which were inhibited by intra-articular injection of [223Ra] RaCl2 (69%, 77%, and 66%, respectively).
Keyphrases
- rheumatoid arthritis
- disease activity
- ankylosing spondylitis
- interstitial lung disease
- inflammatory response
- healthcare
- oxidative stress
- emergency department
- metabolic syndrome
- mental health
- ultrasound guided
- cell proliferation
- skeletal muscle
- drug induced
- cell death
- peripheral blood
- lps induced
- cell cycle arrest
- induced apoptosis
- high glucose